Results 21 to 30 of about 755,873 (344)

Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

Nature Communications, 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
International Multiple Sclerosis Genetics Consortium
doaj   +1 more source

Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity

Journal of Patient Experience, 2021
Pediatric new drug trials are federally mandated, but family perspectives in multiple sclerosis (MS) research are limited. Due to MS chronicity and long-term medical system involvement, we obtained family views on research priorities and optimized ...
Leslie A Mandel PhD, MA, MS, Ellen O’Donnell PhD, Katia Canenguez PhD, EdM, Paola B Castro-Mendoza BSc, MSc, Tim Lotze MD, Emmanuelle Waubant MD, PhD, Bianca Weinstock-Guttmann MD, Tanuja Chitnis MD   +7 more
doaj   +1 more source

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre [PDF]

, 2003
Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting multiple sclerosis (MS). However, the use of this drug in clinical practice is complex, especially because it is only partially effective, its long term ...
Dubois, B.D., Giovannoni, G., Kapoor, R., Keenan, E., Miller, D.H., Porter, B.E,, Rudge, P., Thompson, A.J.   +7 more
core   +2 more sources

Multiple Sclerosis and Schizophrenia [PDF]

International Journal of Molecular Sciences, 2017
The psychiatric and neurological aspects of health may present methodological challenges in the diagnosis and treatment of disease. This is especially true for patients whose symptoms indicate the coexistence of multiple sclerosis (MS) and schizophrenia (SCZ).
Arneth, Borros M, Justus Liebig University Giessen   +1 more
openaire   +6 more sources

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]

Neurology and Therapy, 2023
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, Seth Morgan, June Halper   +4 more
doaj   +1 more source

Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination [PDF]

, 2017
Remyelination is in the center of new therapies for the treatment of multiple sclerosis to resolve and improve disease symptoms and protect axons from further damage.
Bramlett, Brück, Brück, Clark, Cunningham, Foote, Fünfschilling, Gudi, Hiremath, Hiremath, Irvine, Irvine, Kornek, Kuhlmann, Kutzelnigg, Lassmann, Lassmann, Lee, Lindner, Lindner, Lucchinetti, Manrique-Hoyos, Mason, Matsushima, McKenzie, Mildner, Morrison, Murray, Nikic, Otsuka, Patrikios, Pierce, Schuh, Simons, Singh, Skripuletz, Sorbara, Stidworthy, Trapp   +38 more
core   +1 more source

Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study

Frontiers in Neurology, 2023
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses.
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto   +7 more
doaj   +1 more source

Anger, Quality of Life and Mood in Multiple Sclerosis [PDF]

, 2015
This research was funded by The Multiple Sclerosis Society (UK).Peer reviewedPublisher ...
Cooper, Clare L, Hosie, Judith A, Laing, Christianne M, Phillips, Louise H, Summers, Fiona   +4 more
core   +1 more source

Multiple sclerosis

Disease-a-Month, 1996
Multiple sclerosis is a chronic disease that begins in late adolescence or adulthood. It is highly variable in its expression and severity. It is believed to be autoimmune in nature. The cause is unknown; both genetic and environmental factors have been implicated in the pathogenesis. MS generally presents with the acute or subacute onset of neurologic
Lynch, Sharon G., Rose, John W.
openaire   +2 more sources

Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study

Frontiers in Neurology, 2021
Background: Although cognition in multiple sclerosis (MS) is assessed by means of several neuropsychological tests, only a few tools exist to investigate patients' perspectives on cognitive functioning.Objective: To develop a new questionnaire aimed at ...
Alice Riccardi, Francesca Ognibene, Sara Mondini, Massimo Nucci, Monica Margoni, Ilaria Meglioranzi, Elisa Carta, Sofia Zywicki, Silvia Miante, Paola Perini, Francesca Rinaldi, Marco Puthenparampil, Paolo Gallo   +12 more
doaj   +1 more source